Mireille Gillings, PhD, Hon DSc

President, CEO & Executive Chair

Dr. Gillings founded HUYABIO International and has grown this privately held company to become the leader in accelerating the global development of novel biopharmaceutical product opportunities originating in China enabling faster, more cost-effective, and lower-risk drug development in international markets. Through this model, HIYASTA a drug for the treatment of lymphoma was developed and commercialized, in less than 6 years for the Japanese market.

A visionary leader with more than 25 years of proven scientific, clinical, and operational expertise and leadership in the industry, she has also made significant contributions to neurological and neurodegenerative disease research including a focus on neuroactive steroids.

Dr. Gillings was the first woman to be appointed to the Board of Quintiles, post privatization, now IQVIA, a Fortune 500 company; she is co-founder and non Executive Vice Chair of GHO Capital; is a board member of Senté Inc., and serves on the Pasteur Institut US Board.

Among the many honors she has received, the French Government awarded Lady Mireille its highest national award, the Knight of the Legion of Honor. She has been bestowed an Honorary degree by the University of Exeter in 2017, and by Concordia University in 2022, for her business, scientific and philanthropic achievements. The UK Sunday Times has twice named her as one of the top 10 women entrepreneurs. Educated in Canada, the Netherlands, France, and the USA she has a PhD from Radboud University, Nijmegen and post-doctoral fellowships at Bordeaux University and Scripps Institute.